amgen bone news - Search News

Amgen, Obesity and bone mineral density

Zacks.com on MSN · 7h

Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Amgen dismisses bone density concerns related to its weight-loss drug

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.

YAHOO!Finance · 13h

Amgen speaks out about bone density concerns with obesity drug

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data spreadsheet.

1d

Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

1d

What’s Happening With Amgen Stock?

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

1d

Amgen Says No Link Between MariTide And Changes In Bone Mineral Density

Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...

Hosted on MSN1d

Amgen dismisses bone density concerns related to its new weight-loss drug

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results